Here are a few brief analogies for Envista (NVST):

• The Medtronic of dentistry.
• Like a Johnson & Johnson for dental products.

• Dental Implants: Envista offers a comprehensive portfolio of dental implant systems, biomaterials, and prosthetic solutions for tooth replacement.
• Orthodontics: They provide various orthodontic solutions, including clear aligners and traditional braces, for teeth straightening and bite correction.
• Imaging & Digital Solutions: Envista develops and supplies dental imaging equipment, intraoral scanners, and digital workflow software for diagnosis and treatment planning.
• Restoratives & Consumables: They deliver a wide range of dental materials and instruments, such as composites, adhesives, and impression materials, used in general dentistry.

Envista Holdings Corporation (NVST) primarily sells its dental products and solutions to other companies within the dental industry, rather than directly to individual consumers. Its major customers include:

• Dental Distributors: Envista utilizes a network of dental distributors to reach a broad base of dental professionals globally. These distributors purchase products from Envista and then resell them to dental practices, laboratories, and other dental organizations. Two of the largest public dental distributors that likely serve as significant customers or channels for Envista are:
  • Henry Schein, Inc. (HSIC)
  • Patterson Companies, Inc. (PDCO)
• Dental Practices and Clinics: Envista also sells directly to a highly fragmented market of dental professionals, including general dentists, specialists (e.g., orthodontists, oral surgeons, periodontists), and group practices. While these are businesses, they are typically independent or regional entities rather than large public "customer companies."
• Dental Laboratories: These businesses fabricate custom dental prosthetics and devices, often using Envista's materials and equipment.

Therefore, Envista's customer base is predominantly B2B, serving the dental industry through a combination of direct sales and large distributors.

Paul Keel, Chief Executive Officer

Paul Keel was appointed CEO of Envista in May 2024. Prior to joining Envista, he served as Chief Executive Officer and Executive Director at Smiths Group plc from May 2021 to March 2024.

Eric Hammes, Chief Financial Officer

Eric Hammes became Envista's Chief Financial Officer effective August 8, 2024. He previously served as Vice President, Corporate Financial Planning and Analysis at Rockwell Automation. Before Rockwell, Mr. Hammes held numerous financial and operational leadership positions at 3M, including Senior Vice President Controller and Chief Accounting Officer, CFO of 3M Health Care Business Group, and Director Finance for the Orthodontic Products Division.

Robert Befidi, President, Diagnostics

Robert Befidi was appointed President, Diagnostics in December 2023. He joined Envista from 3M, where he was President of the Separation and Purification Sciences Division. Before his time at 3M, Mr. Befidi worked in private equity, consulting, tech, and investment banking research. He co-founded Gordian Capital, a private equity company, where he managed capital raising, deal origination, industry research, transaction structuring, and portfolio management.

Mark Nance, Senior Vice President, General Counsel & Secretary

Mark Nance serves as Senior Vice President, General Counsel & Secretary at Envista Holdings Corporation.

Mischa Reis, Senior Vice President of Strategy & Corporate Development

Mischa Reis holds the position of Senior Vice President of Strategy & Corporate Development at Envista Holdings Corporation.

The rapid advancement and integration of in-office digital manufacturing technologies (such as highly accurate 3D printers and milling machines) combined with sophisticated AI-driven design and treatment planning software. This emerging ecosystem empowers dental practices to produce an increasing array of restorations, prosthetics, and orthodontic appliances (e.g., crowns, bridges, surgical guides, and clear aligners) directly in-house. This trend threatens to disrupt Envista's traditional sales of prefabricated products and lab-dependent solutions across its restorative, implant, and orthodontic segments, potentially commoditizing parts of its portfolio by enabling more cost-effective and immediate alternatives produced by the dentists themselves using third-party systems.

Envista Holdings Corporation (NVST) is a global dental products company with a portfolio spanning various key areas of dentistry. The addressable markets for its main products and services are substantial:

• Global Dental Consumables Market: This broad market, which includes products such as implants, prosthetics, and orthodontics, was valued at approximately USD 36.76 billion in 2024 and is projected to reach USD 73.46 billion by 2033, growing at a CAGR of 8.17% from 2025 to 2033. North America held the largest share of this market in 2024.
• Global Dental Equipment Market: This market, which includes dental imaging systems, was valued at around USD 11.2 billion in 2023 and is projected to reach USD 17.06 billion by 2030, with a CAGR of 6.3% from 2024 to 2030. Another report estimates the market at USD 12.71 billion in 2025, reaching USD 22.1 billion by 2034 with a CAGR of 6.34%. North America dominated the global dental equipment market in 2023.
• Global Dental Implants and Prosthetics Market: Envista is a key player in this segment through its Nobel Biocare and Implant Direct brands. This market is projected to reach USD 18.79 billion by 2030, growing from USD 12.57 billion in 2025 at a CAGR of 8.4%. Another estimate places the global dental implants market size at USD 4.79 billion in 2024, projected to grow to USD 8.17 billion by 2032 with a CAGR of 6.9%. Europe accounted for the largest market share in the global dental implants market.
• Global Orthodontic Supplies Market: Envista is a leading company in the orthodontic supplies market, notably with its Spark clear aligner system and Damon System. The global orthodontic supplies market was valued at USD 6.67 billion in 2024 and is forecasted to reach USD 10.96 billion by 2030, growing at a CAGR of 8.9%. North America leads this market. The global invisible orthodontics market, a sub-segment where Envista's Spark aligners compete, was valued at USD 4.71 billion in 2021 and is predicted to reach USD 14.65 billion by 2030, with a CAGR of approximately 13.42%.
• Global Dental Imaging Market: Envista, through its DEXIS brand (formerly KaVo imaging), is a leader in dental imaging products like intraoral scanners and 3D CBCT systems. This market was valued at approximately USD 3.08 billion in 2024 and is projected to reach USD 4.69 billion by 2030, advancing at a CAGR of 7.5% from 2025 to 2030. Another report indicates the market was valued at USD 6.4 billion in 2022 and is projected to reach USD 14.7 billion by 2032, with a CAGR of 8.7%. North America currently dominates the dental imaging market.

1. Continued Growth and Profitability of Spark Clear Aligners: Envista consistently highlights Spark as a significant growth engine. The company has been gaining market share with Spark aligners and the business achieved positive operating profit in Q3 2025, with expectations for continued margin and market share gains.
2. Commercial and Innovation Investments, Including New Product Launches: Management emphasizes that strategic commercial and innovation investments are yielding beneficial impacts and are central to accelerating growth. Specifically, new product launches supported positive growth across all major businesses in Q3 2025.
3. Improved Performance and Market Share in the Implants Business: Envista is focusing on narrowing the gap relative to the market in its implants business, particularly in North America, with mid-single-digit growth observed in value implants and an improving trend in Nobel. These efforts are anticipated to contribute to future revenue expansion in this segment.
4. Strategic Price Increases: The company has demonstrated the ability to realize positive price growth in key product categories, including Spark aligners and brackets and wires businesses, indicating that strategic pricing will continue to be a component of revenue growth.
5. Leveraging the Envista Business System (EBS) for Operational Excellence: While primarily an operational improvement strategy, the ongoing contributions from the Envista Business System (EBS) are crucial for sustained operational improvement, which indirectly supports revenue growth by enhancing efficiency and profitability, as seen with Spark achieving positive operating margin.

Share Repurchases

• Envista Holdings Corp authorized a stock repurchase program of up to $250 million through December 31, 2026, announced on February 5, 2025.
• During the third quarter ended September 26, 2025, Envista repurchased approximately $41 million worth of shares, totaling 2.1 million shares.
• For the nine months ended September 26, 2025, share repurchases amounted to approximately $141.9 million for 8.0 million shares. At the end of that quarter, $108 million remained under the repurchase authorization.

Outbound Investments

• In May 2022, Envista entered into a definitive agreement to acquire Osteogenics Biomedical Inc., Allotech LLC, and OBI Biologics, Inc. ("Osteogenics"), a leader in regenerative solutions for implant dentistry.
• Envista completed the acquisition of Carestream Dental's Intra-Oral Scanner (IOS) business for $600 million in April 2022.
• In December 2021, Envista closed the divestiture of its KaVo Treatment Unit & Instrument business, receiving $317.3 million.

Capital Expenditures

• In 2024, Envista invested an incremental $25 million in commercial coverage, clinical education, and new product development.
• The company generated over $220 million of free cash flow in 2023 and continued to invest in strategic priorities aimed at accelerating growth and enhancing margins.
• Envista invested in several Kaizen projects in 2023, focusing on enhancing sustainability and operational efficiency, particularly related to waste generation and energy use at various facilities.